Zoetis Inc. has reintroduced Zoamix (zoalene), a versatile synthetic anticoccidial for the prevention and control of coccidiosis in broilers and turkeys.
“The U.S. poultry industry loses an estimated $600 million a year to coccidiosis, so the return of Zoamix could not be coming at a better time,” said Don Waldrip, DVM, DACPV, a senior technical services veterinarian with Zoetis.
He noted that U.S. poultry producers have not seen a new in-feed anticoccidial in 15 years, and concerns remain about existing products becoming less effective over time. “Having one more anticoccidial to use in a rotation program — especially one like Zoamix, which has a unique chemical structure — could help preserve the efficacy of other coccidiosis medications,” Waldrip said.
Waldrip said the arrival of Zoamix would further strengthen Rotecc Coccidiosis Management, a science-based initiative Zoetis launched earlier this year to help poultry producers develop more strategic, cost-effective and sustainable programs for battling the costly parasitic disease.
More uses
In addition to preventing and controlling coccidiosis in broilers and turkeys, Zoamix can be used for the development of active immunity against coccidiosis in replacement chickens. Zoamix is also approved for use in combination with BMD (bacitracin methylene disalicylate), a feed medication used to manage necrotic enteritis in chickens and transmissible enteritis in turkeys.
Formerly produced by Alpharma, Zoamix was used by the U.S. broiler and turkey industries for more than four decades before leaving the market in 2005 due to shortage of a key ingredient. Zoetis later acquired the product, saw the poultry industry’s need for Zoamix, and worked with suppliers to resolve supply issues and relaunch the product.